Key Takeaways
- Revenue up 9.2%, margins squeezed: Net revenue grew 9.2% YoY, but EBITDA margin fell to 14.6% from 15% a year ago, weighed down by remediation costs, a VRS charge, and a deliberate weeding of the domestic product tail.
- Europe degrew sharply on a single customer: Europe revenue fell 32% YoY (to ₹58.2 crore) because one large Paracetamol customer stopped ordering, likely due to overstocking; a turnaround is expected from April/May.
- US business on track for ₹300 crore: The US business grew 43.2% and is expected to end the year very close to the ₹300 crore mark, with Goa Plant 1 clearing a pre-approval inspection and more approvals expected.
- Domestic growth is healthier than it looks: Reported 4.4% domestic growth is depressed by institutional business fluctuations and the wind-down of 150+ small products; IQVIA covered-market growth was 12.8%, and the tail wash-out should end this fiscal year.
- What to watch next quarter: Whether Europe orders resume in February as guided, whether remediation costs actually drop off after one more quarter, and whether the domestic tail wind-down completes to give a clean base for FY2025.
Europe: The Quarter's Biggest Drag
- Paracetamol order drop-off: Europe revenue fell to ₹58.2 crore from ₹86 crore a year ago, almost entirely because one large customer stopped ordering Paracetamol, possibly because they are overstocked; no Red Sea impact has yet materialized.
- Low-margin contract manufacturing dominates: 90% of Europe revenue is contract manufacturing for others; higher-value products have been filed but approvals are slow post-COVID.
- Turnaround pinned on new approvals: Management expects Europe to turn around from February, with new product approvals likely from April/May, which would allow the company to shed low-margin Paracetamol business and improve both top and bottom line.
- Baddi site now EU-ready: The Baddi site has received all European approvals, and products are being transferred from Goa 1 to Baddi 3 for the EU market.
Aditi Panandikar: "this quarter's performance does not yet have any impact of the Red Sea issues. I think the Europe picture that you are seeing is largely an impact of Paracetamol from one customer orders steady state not coming in possibly because they are overstocked."
Domestic Business: Tail Wind-Down Masks Underlying Health
- Reported growth understates momentum: Domestic formulation grew 4.4% YoY, but this is depressed by institutional/tender business fluctuations and a high base; IQVIA data shows 12.8% growth against a covered market growth of 8%, indicating healthy demand.
- Product portfolio weeding underway: The company is winding down a tail of 150+ small, strategically irrelevant products, which cost ₹3-4 crore in revenue this quarter; new product introductions added roughly ₹7 crore, so the net impact was still positive.
- Acute-heavy portfolio hit by weak season: The second-largest brand, Febrex Plus, degrew 3.5% as the respiratory market shifts post-COVID toward plain Paracetamol or anti-allergic products; solid oral formulations grew, with the decline isolated to the liquid oral SKU.
- Weeding to end this fiscal year: The tail wind-down is expected to complete within FY2024, giving FY2025 a clean base from which all incremental new-launch revenue will flow through.
- Anti-infective brand Oxipod performed well this quarter after a lull in the first half.
Aditi Panandikar: "if you look at our performance for Q3 as per AVAX then against a covered market growth of 8% we are actually growing at 12.8% this quarter. That shows very healthy demand for our products."
US Business: Ramping Toward ₹300 Crore
- Strong growth, near-target exit: US business grew 43.2% YoY; last year's revenue was ₹266 crore and management expects to end this year very close to the ₹300 crore figure mentioned by an analyst.
- Goa Plant 1 cleared: The plant received an EIR from USFDA for a pre-approval inspection, and more US approvals are expected soon; batch sizes have been increased for some products, which will lower manufacturing cost and expand margins.
- Tentative ANDA for Canagliflozin: A tentative ANDA approval was received for Canagliflozin 100mg and 300mg tablets, an SGLT2 inhibitor.
- SPP acquisition provides front-end control: The company acquired SPP to have its own front-end in the US and control the fortunes of its products there.
- Two to three more US approvals are possible in a year's time.
Sundeep Bambolkar: "As we said futuristic statements not everything is under our control. Geopolitics is playing a huge spoil sport but still we are trying our best. Last year we had done Rs.266 Crores and this year we will end up very close to the figure you mentioned."
Margins: Multiple Headwinds, Some Transitory
- EBITDA margin compressed to 14.6% from 15% a year ago, while PAT margin fell to 6.3% from 6.8%; for 9M, the drop was steeper: EBITDA margin at 15.1% vs. 18.2%.
- Remediation costs persist: Expenditure on the remediation partner and site improvements for FDA compliance at Goa Plant 2 continued at similar levels and are expected to last one more quarter.
- VRS scheme added a one-off employee cost: A voluntary retirement scheme at one Goa plant pushed up employee costs this quarter; the impact is expected to be recovered within two years.
- Gross margin improved: Material cost as a percentage of sales fell to 30.5%, the best in six quarters, versus 31.7% a year ago.
- Sales promotion spend rose for digital sales and marketing (B2C model), with impact on sales growth expected in another couple of quarters.
- Other expenses declined sequentially from ₹145 crore to ₹140 crore due to cost-control efforts, despite similar remediation costs.
- Depreciation increased due to incremental depreciation on fixed assets capitalized over the last three quarters and amortization of ANDA costs.
API & Other Businesses: Diversification Paying Off
- API business grew 105% as internal consumption by the international formulation business dropped from 60% to 30% of capacity, freeing up volume for external sales and a better client base.
- AnaCipher/Indoco Analytical Solutions grew 70% and won "Best Customer Service Provider in Pharma and Healthcare" at the Pharma and Health Tech Summit and Awards 2023.
- Emerging markets grew 37.3%, contributing to the international formulation growth of 4.6%.
- API business will continue to ramp up in the coming years.
Capacity & Long-Term Ambition
- Current capacity can generate 2.5 to 3 times the current annual top line from Europe and the US, implying significant operating leverage once utilization rises.
- International margins targeted at 20% EBITDA: Once aligned and executed properly, management believes 20% EBITDA margin is achievable in US and Europe.
- 3x business size in five years: A target stated 15 months ago remains the company's long-term ambition.
- Capex for FY2025 is expected to be at similar levels to FY2024 (₹150 crore) or slightly lower.
- Goa Plant 2 FDA re-inspection is expected in the second half of next year (Q3 FY2025 at the earliest), though no exact date has been communicated by the FDA.
Aditi Panandikar: "Actually this capacity can give us anywhere from 2.5 to 3 times the top line."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US business revenue | End the year very close to ₹300 crore | FY2024 exit |
| Remediation costs | Similar level of costs to continue, then drop off | One more quarter |
| Europe turnaround | Orders resume; new product approvals drive visible improvement | From February (orders), April/May (approvals) |
| Domestic product tail wind-down | Weeding of 150+ small products to complete | By end of FY2024 |
| Tax rate | Remain at concessional rate of 25% | Ongoing |
| Capex | Similar to FY2024 (₹150 crore) or slightly lower | FY2025 |
| Goa Plant 2 FDA re-inspection | Expected in second half of next year | Q3 FY2025 earliest |
| US ANDA approvals | Two to three approvals possible | Within a year |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Net revenue | ₹448.4 cr, +9.2% YoY vs ₹410.6 cr |
| EBITDA margin | 14.6%, vs 15% in Q3 FY23 |
| PAT before exceptional items margin | 6.3% at ₹28.2 cr, vs 6.8% at ₹27.9 cr in Q3 FY23 |
| EPS | ₹2.17, vs ₹3.02 in Q3 FY23 |
| Domestic formulation revenue | ₹212.6 cr, +4.4% YoY vs ₹203.6 cr |
| International formulation revenue | ₹194.7 cr, +4.6% YoY vs ₹186.1 cr |
| US business revenue | ₹86.3 cr, +43.2% YoY vs ₹60.3 cr |
| Europe revenue | ₹58.2 cr, degrowth vs ₹86 cr in Q3 FY23 |
| Emerging markets revenue | ₹47.2 cr, +37.3% YoY vs ₹34.4 cr |
| API business revenue | ₹33.3 cr, +105% YoY vs ₹16.2 cr |
| AnaCipher CRO and Indoco Analytical Solutions revenue | ₹7.8 cr, +70% YoY vs ₹4.6 cr |
| Material cost as % of sales | 30.5%, vs 31.7% in Q3 FY23 |
| One-off costs (remediation plus VRS) | ~₹13–15 cr (management estimate) |
| Domestic covered market growth (AWACS) | 12.8% for Indoco vs 8% market growth |
| Domestic MR count on payroll | 2,300 |
| Capex expected for FY24 | ₹150 cr |